Kristina Jonsson-Schmunk1, Romi Ghose2, Maria A Croyle1,3. 1. Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas, Austin, Texas, USA. 2. Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, Texas, USA. 3. LaMontagne Center for Infectious Disease, The University of Texas at Austin, Austin, Texas, USA.
Abstract
OBJECTIVE: Infectious disease emergencies like the 2013-2016 Ebola epidemic and the 2009 influenza and current SARS-CoV-2 pandemics illustrate that vaccines are now given to diverse populations with preexisting pathologies requiring pharmacological management. Many natural biomolecules (steroid hormones, fatty acids, vitamins) and ~60% of prescribed medications are processed by hepatic cytochrome P450 (CYP) 3A4. The objective of this work was to determine the impact of infection and vaccines on drug metabolism. METHODS: The impact of an adenovirus-based vaccine expressing Ebola glycoprotein (AdEBO) and H1N1 and H3N2 influenza viruses on hepatic CYP 3A4 and associated nuclear receptors was evaluated in human hepatocytes (HC-04 cells) and in mice. RESULTS: CYP3A activity was suppressed by 55% in mice 24 h after administration of mouse-adapted H1N1, while ˂10% activity remained in HC-04 cells after infection with H1N1 and H3N2 due to global suppression of cellular translation capacity, indicated by reduction (70%, H1N1, 56%, H3N2) of phosphorylated eukaryotic translation initiation factor 4e (eIF4E). AdEBO suppressed CYP3A activity in vivo (44%) and in vitro (26%) 24 hours after infection. CONCLUSION: As the clinical evaluation of vaccines for SARS-CoV-2 and other global pathogens rise, studies to evaluate the impact of new vaccines and emerging pathogens on CYP3A4 and other metabolic enzymes are warranted to avoid therapeutic failures that could further compromise the public health during infectious disease emergencies.
OBJECTIVE: Infectious disease emergencies like the 2013-2016 Ebola epidemic and the 2009 influenza and current SARS-CoV-2 pandemics illustrate that vaccines are now given to diverse populations with preexisting pathologies requiring pharmacological management. Many natural biomolecules (steroid hormones, fatty acids, vitamins) and ~60% of prescribed medications are processed by hepatic cytochrome P450 (CYP) 3A4. The objective of this work was to determine the impact of infection and vaccines on drug metabolism. METHODS: The impact of an adenovirus-based vaccine expressing Ebola glycoprotein (AdEBO) and H1N1 and H3N2 influenza viruses on hepatic CYP 3A4 and associated nuclear receptors was evaluated in human hepatocytes (HC-04 cells) and in mice. RESULTS: CYP3A activity was suppressed by 55% in mice 24 h after administration of mouse-adapted H1N1, while ˂10% activity remained in HC-04 cells after infection with H1N1 and H3N2 due to global suppression of cellular translation capacity, indicated by reduction (70%, H1N1, 56%, H3N2) of phosphorylated eukaryotic translation initiation factor 4e (eIF4E). AdEBO suppressed CYP3A activity in vivo (44%) and in vitro (26%) 24 hours after infection. CONCLUSION: As the clinical evaluation of vaccines for SARS-CoV-2 and other global pathogens rise, studies to evaluate the impact of new vaccines and emerging pathogens on CYP3A4 and other metabolic enzymes are warranted to avoid therapeutic failures that could further compromise the public health during infectious disease emergencies.
Entities:
Keywords:
Cytochrome P450 3A4; drug metabolism; ebola; influenza; liver; vaccine
Authors: Rebekah Honce; Nicholas Wohlgemuth; Victoria A Meliopoulos; Kirsty R Short; Stacey Schultz-Cherry Journal: Cold Spring Harb Perspect Med Date: 2020-12-01 Impact factor: 6.915
Authors: T Fislová; M Gocník; T Sládková; V Durmanová; J Rajcáni; E Varecková; V Mucha; F Kostolanský Journal: Arch Virol Date: 2009-02-03 Impact factor: 2.574
Authors: Anima Ghosal; Samir Gupta; Ragu Ramanathan; Yuan Yuan; Xiaowen Lu; Ai Duen Iris Su; Narciso Alvarez; Shmuel Zbaida; Swapan K Chowdhury; Kevin B Alton Journal: Drug Metab Lett Date: 2009-08-01
Authors: Oly Ilunga Kalenga; Matshidiso Moeti; Annie Sparrow; Vinh-Kim Nguyen; Daniel Lucey; Tedros A Ghebreyesus Journal: N Engl J Med Date: 2019-05-29 Impact factor: 91.245
Authors: Jordan R Barrett; Sandra Belij-Rammerstorfer; Christina Dold; Katie J Ewer; Pedro M Folegatti; Ciaran Gilbride; Rachel Halkerston; Jennifer Hill; Daniel Jenkin; Lisa Stockdale; Marije K Verheul; Catherine M Green; Adrian V S Hill; Teresa Lambe; Sarah Gilbert; Andrew J Pollard; Parvinder K Aley; Brian Angus; Duncan Bellamy; Eleanor Berrie; Sagida Bibi; Mustapha Bittaye; Miles W Carroll; Breeze Cavell; Elizabeth A Clutterbuck; Nick Edwards; Amy Flaxman; Michelle Fuskova; Andrew Gorringe; Bassam Hallis; Simon Kerridge; Alison M Lawrie; Aline Linder; Xinxue Liu; Meera Madhavan; Rebecca Makinson; Jack Mellors; Angela Minassian; Maria Moore; Yama Mujadidi; Emma Plested; Ian Poulton; Maheshi N Ramasamy; Hannah Robinson; Christine S Rollier; Rinn Song; Matthew D Snape; Richard Tarrant; Stephen Taylor; Kelly M Thomas; Merryn Voysey; Marion E E Watson; Daniel Wright; Alexander D Douglas Journal: Nat Med Date: 2020-12-17 Impact factor: 53.440
Authors: Yun Zhang; Brian D Aevermann; Tavis K Anderson; David F Burke; Gwenaelle Dauphin; Zhiping Gu; Sherry He; Sanjeev Kumar; Christopher N Larsen; Alexandra J Lee; Xiaomei Li; Catherine Macken; Colin Mahaffey; Brett E Pickett; Brian Reardon; Thomas Smith; Lucy Stewart; Christian Suloway; Guangyu Sun; Lei Tong; Amy L Vincent; Bryan Walters; Sam Zaremba; Hongtao Zhao; Liwei Zhou; Christian Zmasek; Edward B Klem; Richard H Scheuermann Journal: Nucleic Acids Res Date: 2016-09-26 Impact factor: 16.971